• Anti-neuronal nuclear Ab type 1
• Anti-neuronal nuclear Ab type 2
• Anti-neuronal nuclear Ab type 3
• Anti-glial nuclear Ab type 1
• Purkinje cell cytoplasmic Ab type 1
• Purkinje cell cytoplasmic Ab type 2
• Purkinje cell cytoplasmic Ab type Tr
• Amphiphysin Ab  
• CRMP-5-IgG
• Striational (striated muscle) Ab
• P/Q-type calcium channel Ab
• N-type calcium channel Ab
• AChR ganglionic neuronal Ab

Reflex testing when indicated performed at an additional charge:

• ACh receptor (muscle) binding Ab
• ACh Receptor (Muscle) modulating Ab
• AGNA-1 immunoblot
• AMPA-R Ab CBA
• AMPA-R Ab IF titer assay
• Amphiphysin immunoblot
• ANNA-1 immunoblot
• ANNA-2 immunoblot
• CASPR2-IgG CBA
• CRMP-5-IgG western blot
• DPPX Ab CBA
• DPPX Ab IFA
• DPPX Ab IFA titer
• GABA-B-R Ab CBA
• GABA-B-R Ab IF titer
• GAD65 Ab assay
• LGI1-IgG CBA
• mGIuR1 Ab CBA
• mGIuR1 Ab
• MGIuR1 Ab IFA titer
• NMDA-R Ab
• NMDA-R Ab titer
• PCA-1 immunoblot
• PCA-Tr immunoblot

Mayo Paraneoplastic Evaluation Algorithm

• Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer
• Directing a focused search for cancer
• Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis
• Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
• Monitoring the immune response of seropositive patients in the course of cancer therapy
• Detecting early evidence of cancer recurrence in previously seropositive patients